ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

NEW YORK, January 28, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology ...

The Division of Anatomic Pathology at the University of Alabama at Birmingham, offers a one-year fellowship experience in Genitourinary (GU) pathology. The University of Alabama at Birmingham (UAB) ...

This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...

Within the genitourinary cancer space, there have been many treatment advances over the past year. For patients with bladder cancer, exciting innovations in treatment have arrived, as we detail in ...

Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

Although modern three-dimensional (3D) conformal radiotherapy has allowed to reach a total dose that increases local control with acceptable treatment toxicity, 1, 2 each of these treatments can ...

The study included a total of 183 patients with genitourinary cancers. Immunity against SARS-CoV-2 appears to wane over time in genitourinary cancer patients following COVID-19 vaccination, suggesting ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...